BridgeBio Pharma
BBIO
66.50
-0.46
-0.69%
BridgeBio Pharma
US · BBIO
#1254 by market cap
Listed 2019
66.50
-0.46
-0.69%
Live - 5344 symbols - heartbeat 80s ago
· 2026-10-08 05:32
Pre-market
66.30
-0.30%
After-hours
65.99
-0.77%
Overnight
66.50
0.00%
- Market cap
- 13.00B
- P/E (TTM)i
- -18.68
- P/Bi
- -5.17
- EPSi
- -3.78
- Div yieldi
- 0.00%
- 52W posi
- 34%
Reader sentiment
Are you bullish or bearish on BBIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 2.5 percentage points.
Institutional ownership
- Held by institutions
- 98.04% -2.45pp
- Institutions
- 566 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund56.26%
Hedge Fund24.42%
VC/PE Fund8.67%
Individual/Insider3.93%
Private Company3.87%
Public Company3.06%
Sovereign Wealth Fund0.87%
Government Pension Fund0.65%
Insurance Company0.16%
Top holders as of 2026-06-30
Janus Henderson Group plc
7.22% · 14.11M sh
Farallon Capital Management, L.L.C.
5.50% · 10.74M sh
BlackRock
5.26% · 10.29M sh
Viking Global Investors LP
5.01% · 9.79M sh
Vanguard Capital Management, LLC
4.61% · 9.02M sh
KKR & Co. Inc.
4.23% · 8.26M sh
Vanguard Portfolio Management, LLC
3.92% · 7.66M sh
Wellington Management Group
2.72% · 5.31M sh
Neil Kumar
2.59% · 5.06M sh
Two Sigma Investments, LP
2.42% · 4.72M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Neil Kumar | Chief Executive Officer | 2.59% |
| Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | 0.47% |
| Frank McCormick | Co-Founder & Chairman of Oncology | 0.39% |
| Thomas Trimarchi | Chief Product Officer | 0.17% |
| Ali Satvat | Independent Director | 0.08% |
| Maricel Apuli | Chief Accounting Officer | 0.06% |
| Brian Stephenson | Chief Financial Officer | 0.05% |
| James Momtazee | Director | 0.05% |
| Wen-Chaun Lo | Independent Director | 0.03% |
| Douglas Dachille | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | Neil Kumar | Chief Executive Officer | Automatic Disposition | -10,000 | $69.01–69.57 |
| 2026-08-18 | Neil Kumar | Chief Executive Officer | Automatic Disposition | -44,980 | $81.15–85.65 |
| 2026-08-17 | Neil Kumar | Chief Executive Officer | Intent to Sell (Form 144) | -34,980 | $79.89 |
| 2026-08-16 | Randal Scott | Independent Director | Intent to Sell (Form 144) | -21,501 | $79.86 |
| 2026-08-15 | Neil Kumar | Chief Executive Officer | Derivative Exercise and Sale | -36,237 | $79.86 |
| 2026-08-15 | Neil Kumar | Chief Executive Officer | Derivative Exercise and Retained | +34,980 | -- |
| 2026-08-15 | Thomas Trimarchi | Chief Product Officer | Sale to Issuer | -22,781 | $79.86 |
| 2026-08-15 | Maricel Apuli | Chief Accounting Officer | Sale to Issuer | -4,714 | $79.86 |
| 2026-07-29 | Maricel Apuli | Chief Accounting Officer | Automatic Disposition | -2,000 | $80.06 |
| 2026-07-08 | Jennifer Cook | Director | Derivative Exercise and Sale | -148,589 | $8.45–90.00 |
| 2026-07-08 | Andrea Ellis | Independent Director | Derivative Exercise and Sale | -17,167 | $16.75–84.00 |
| 2026-06-23 | Randal Scott | Independent Director | Intent to Sell (Form 144) | -2,196 | $68.63 |
| 2026-06-23 | Jennifer Cook | Director | Derivative Exercise and Sale | -37,167 | $8.45–70.00 |
| 2026-06-22 | Jennifer Cook | Director | Automatic Disposition | -2,196 | $68.57 |
| 2026-06-22 | Hannah Valantine | Independent Director | Automatic Disposition | -2,196 | $68.57 |
| 2026-06-21 | Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | Other Acquisition | +3,990 | -- |
| 2026-06-21 | Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | Other Derivative Acquisition | +5,277 | $68.92 |
| 2026-06-21 | Fred Hassan | Independent Director | Other Acquisition | +3,990 | -- |
| 2026-06-21 | Fred Hassan | Independent Director | Other Derivative Acquisition | +5,277 | $68.92 |
| 2026-06-21 | Ronald Daniels | Independent Director | Other Acquisition | +3,990 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:32:13 · For reference only, not investment advice and not tailored to your situation.